Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

INTRODUCTION: Anti-TNF-α therapy of Crohn’s disease (CD) represents considerable progress in inflammatory bowel disease (IBD) treatment; however, many patients still require surgical intervention. The Polish National Insurance Fund currently only covers up to 2 years of infliximab (IFX) therapy in C...

Descripción completa

Detalles Bibliográficos
Autores principales: Sochal, Marcin, Krzywdzińska, Monika, Gabryelska, Agata, Talar-Wojnarowska, Renata, Małecka-Panas, Ewa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294981/
https://www.ncbi.nlm.nih.gov/pubmed/32550949
http://dx.doi.org/10.5114/pg.2019.90079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294981/
https://www.ncbi.nlm.nih.gov/pubmed/32550949
http://dx.doi.org/10.5114/pg.2019.90079

Ejemplares similares